Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Total Revenue of $17.26 billion for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $17.26B +4.3% |
$16.54B +4.4% |
$15.85B +6.2% |
$14.93B -6.0% |
$15.88B -4.7% |
$16.66B -1.4% |
| Revenue (ASC 606) | $17.26B +4.3% |
$16.54B +4.4% |
$15.85B +6.2% |
$14.93B -6.0% |
$15.88B -4.7% |
$16.66B -1.4% |
| Net Income | $1.41B +186.0% |
-$1.64B -193.2% |
-$559.00M +77.1% |
-$2.45B -686.6% |
$417.00M +110.5% |
-$3.99B -299.4% |
| Diluted EPS | $1.21 +183.4% |
-$1.45 -190.0% |
-$0.50 +77.3% |
-$2.20 -678.9% |
$0.38 +110.4% |
-$3.64 -300.0% |
| Total Assets | $40.75B +3.6% |
$39.33B -9.5% |
$43.46B -5.4% |
$45.93B -3.6% |
$47.67B -5.9% |
$50.64B -11.9% |
| Cash and Equivalents | $3.56B +7.8% |
$3.30B +2.3% |
$3.23B +15.2% |
$2.80B +29.4% |
$2.17B -0.6% |
$2.18B +10.2% |
| Stockholders Equity | $7.91B +47.2% |
$5.37B -36.8% |
$8.50B -13.3% |
$9.81B -4.6% |
$10.28B +2.5% |
$10.03B -28.2% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | $2.16B +811.9% |
-$303.00M -170.0% |
$433.00M +119.7% |
-$2.20B -228.0% |
$1.72B +148.0% |
-$3.57B -706.3% |
| Gross Profit | $8.94B +10.8% |
$8.06B +5.5% |
$7.64B +9.6% |
$6.97B -8.2% |
$7.59B -1.7% |
$7.73B +2.5% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $4.48B | +3.4% | +7.3% |
| Revenue (ASC 606) | September 30, 2025 | $4.48B | +3.4% | +7.3% |
| Net Income | September 30, 2025 | $433.00M | +199.1% | +53.5% |
| Diluted EPS | September 30, 2025 | $0.37 | +194.9% | +54.2% |
| Total Assets | September 30, 2025 | $39.86B | -4.6% | -0.7% |
| Cash and Equivalents | September 30, 2025 | $2.20B | -33.6% | +1.9% |
| Stockholders Equity | September 30, 2025 | $7.25B | +19.5% | +6.2% |
| R&D Expense | March 31, 2018 | $54.00M | — | — |
| Operating Income | September 30, 2025 | $882.00M | +1829.4% | +93.8% |
| Gross Profit | September 30, 2025 | $2.30B | +7.3% | +9.6% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Total Revenue of $17.26 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +4.3% in Total Revenue compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Revenue (ASC 606) of $17.26 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Net Income of $1.41 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +186.0% in Net Income compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Diluted EPS of $1.21 per share for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +183.4% in Diluted EPS compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Total Assets of $40.75 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +3.6% in Total Assets compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Cash and Equivalents of $3.56 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +7.8% in Cash and Equivalents compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Stockholders Equity of $7.91 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +47.2% in Stockholders Equity compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported R&D Expense of $114.00 million for fiscal year 2018.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed a decrease of -34.9% in R&D Expense compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Operating Income of $2.16 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +811.9% in Operating Income compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Gross Profit of $8.94 billion for fiscal year 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +10.8% in Gross Profit compared to the prior fiscal year.
- TEVA PHARMACEUTICAL INDUSTRIES LTD reported Shares Outstanding of 937.00 million shares for fiscal year 2010.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +1.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: